PTO/SB/08a (01-10) Approved for use through 07/31/2012 OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE io a collection of information unless it contains a valid OMB control number

Remove

Pages, Columns, Lines where

Τ۶

	Application Number		10596050	
	Filing Date		2007-01-24	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor Colle		llet et al.	
	Art Unit		2442	
	Examiner Name	MacIlwinen, J.		
	Attorney Docket Numb	er	FR920030070US1	

U.S. PATENTS

Name of Patentee or Applicant

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	late	Name of Pate of cited Docu	entee or Applicant ment	Rele	vant Passages or Releves es Appear	
	1									
If you wish	If you wish to add additional U.S. Patent citation information please click the Add button. Add									
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite N	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20020112008	A1	2002-08	-15	Christenson et	al.			
If you wish	h to ad	d additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d butto	n. Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*		Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

publisher, city and/or country where published.

Examiner Cite

Initials\* No

#### 

	1	APOSTOLESCU, International Application No. PCT/FP2004/052907, PCT International Search Report, February 3, 2005, 4 pages.					
	2	APOSTOLESCU, International Application No. PCT/EP2004/052907, PCT Written Opinion of the International Searching Authority, March 4, 2005, 5 pages.					
	3	TOSCANO, International Application No. PCT/EP2004/052907, PCT Preliminary Report on Patentability, February 2, 2006					
If you wish to add additional non-patent literature document citation information please click the Add button Add							

Examiner Signature Date Considered Date Considered FEXAMINEE: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patient Documents at <a href="https://www.USPTO.GDV">www.USPTO.GDV</a> or MPEP 901 DA. <sup>2</sup> Enter office that asseed the document, by the two-letter code (WIPO Standard ST 3). <sup>3</sup> For Japanese patent documents, the indication of the year of the steps of the Enterport must precide the search under of the patent document. <sup>3</sup> Wind of document for the year porting explorates an included of the document under WIPO document of the WIPO document ST Applicate to be patent as check many here of the patent document for the WIPO do

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10596050		
Filing Date		2007-01-24		
First Named Inventor	Collet	et al.		
Art Unit		2442		
Examiner Name	MacIh	MacIlwinen, J.		
Attorney Docket Number		FR920030070US1		

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Elaine Chi Berlin/	Date (YYYY-MM-DD)	2011-08-25
Name/Print	Elaine Chi Berlin	Registration Number	61194

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

#### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursyant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
  the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
  may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
  an application which became abandoned or in which the proceedings were terminated and which application is
  referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.